

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/317186990>

Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA

Article in *European Journal of Nuclear Medicine* · May 2017

DOI: 10.1007/s00259-017-3728-y

CITATIONS

51

14 authors, including:



Murat Fani Bozkurt

Hacettepe University

78 PUBLICATIONS 647 CITATIONS

[SEE PROFILE](#)



Mohsen Beheshti

University Hospital RWTH Aachen

119 PUBLICATIONS 2,665 CITATIONS

[SEE PROFILE](#)

READS

619



Sona Balogova

Hôpital Tenon (Hôpitaux Universitaires Est Parisien)

79 PUBLICATIONS 879 CITATIONS

[SEE PROFILE](#)



Doemnico Rubello

770 PUBLICATIONS 13,844 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:




HyperPET [View project](#)



Bone metastasis imaging [View project](#)

Guideline for PET/CT imaging of neuroendocrine neoplasms with ^{68}Ga -DOTA-conjugated somatostatin receptor targeting peptides and ^{18}F -DOPA

Murat Fani Bozkurt¹  · Irene Virgolini² · Sona Balogova^{3,4} · Mohsen Beheshti^{5,6} · Domenico Rubello⁷ · Clemens Decristoforo² · Valentina Ambrosini⁸ · Andreas Kjaer⁹ · Roberto Delgado-Bolton¹⁰ · Jolanta Kunikowska¹¹ · Wim J. G. Oyen¹² · Arturo Chiti¹³ · Francesco Giammarile¹⁴ · Stefano Fanti⁸

Received: 5 May 2017 / Accepted: 9 May 2017
© Springer-Verlag Berlin Heidelberg 2017

Abstract

Purpose & Methods Neuroendocrine neoplasms are a heterogeneous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using ^{68}Ga -DOTA-conjugated peptides, as well as ^{18}F -DOPA imaging for various neuroendocrine neoplasms.

Results & Conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with ^{68}Ga -conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

Keywords Neuroendocrine tumours · Neuroendocrine neoplasms · Pet/Ct · ^{68}Ga -DOTATATE · ^{68}Ga -DOTATOC · ^{68}Ga -DOTANOC · ^{18}F -DOPA · ^{18}F -FDG · Thyroid medullary cancer · Pheochromocytoma · Paraganglioma · Foregut-NET · Midgut-NET · Hindgut-NET · Hyperinsulism in infants

Background information and definitions

Neuroendocrine neoplasms (NENs) are a heterogeneous group of diverse neoplasms that originate from cells of neuroendocrine origin in many different organs but more frequently from

✉ Murat Fani Bozkurt
fanibozkurt@yahoo.com

✉ Roberto Delgado-Bolton
rbolton@gmail.com

¹ Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, Turkey

² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

³ Department of Nuclear Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia

⁴ Department of Nuclear Medicine, Tenon Hospital AP-HP & Université Pierre et Marie Curie, Paris, France

⁵ PET-CT Center, Department of Nuclear Medicine & Endocrinology, St. Vincent's Hospital, Linz, Austria

⁶ Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, Austria

⁷ Department of Nuclear Medicine, PET Center and Medical Physics and Radiology, Santa Maria della Misericordia Hospital, Rovigo, Italy

⁸ Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy

⁹ Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark

¹⁰ Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, Spain

¹¹ Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland

¹² Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

¹³ Nuclear Medicine Department, Humanitas University, Rozzano, MI, Italy

¹⁴ Nuclear Medicine, University of Lyon, Lyon, France